Home > Press > DermAvance Pharmaceuticals Announces Investment by Ben Franklin Technology Partners of Southeastern Pennsylvania
Abstract:
DermAvance Pharmaceuticals, a privately held pharmaceutical company specializing in advanced technology applications for skin health and cosmetic dermatology, today announced it had received an investment from Ben Franklin Technology Partners of Southeastern Pennsylvania (BFTP/SEP). These funds are part of a Series B financing that will be used to complete the acquisition and commercialization of DA-007, a patent protected combination, second generation dermal filler.
Dermal fillers are used to reverse changes associated with aging and can reduce or eliminate wrinkles, raise scar depressions, enhance lips and replace soft-tissue volume loss, thus returning the dermis to its original youthful state. Current marketed fillers include market-leader Restylane, sold by Medicis Pharmaceutical, and Radiesse sold by Bioform.
"We were very pleased to be selected for an investment by Ben Franklin Technology Partners as a part of our Series B financing," says Keith Greathouse, DermAvance President and CEO. Partnering with Ben Franklin validates our technology and represents a significant step in our on-going financing plan for the company. We continue to speak with additional investors to augment this initial investment and expect to complete the Series B financing during the third quarter. The proceeds from the Series B financing will be used to in part to also prepare and file the registration package for U.S marketing approval and to plan for the commercial launch of DA-007.
Mr. Greathouse further stated that physicians and patients desire dermal fillers like DA-007 that are safe, non-animal derived, long-lasting, easy to administer, and cost effective. The facial regeneration market is emerging as a powerful force with the baby boomers coming of age, and the US dermal filler market is projected to reach $1 billion by 2012.
####
About DermAvance Pharmaceuticals
DermAvance Pharmaceuticals, Inc. is a privately held dermatology pharmaceutical company focused on commercializing unique, and innovative anti- aging products to enhance the health and appearance of skin. The company was founded to meet the rapidly growing demand for facial skin rejuvenation products. DermAvance already has launched four product lines in this explosive anti-aging category including: Hyalogy (nano hyaluronic acid), Vivelif(R) (acetyl hexapeptide-3), Arnika Forte to reduce bruising, and SOYA. DermAvance markets and sells products directly to dermatologists and aesthetic physicians for in-office dispensing.
About Ben Franklin Technology Partners of Southeastern Pennsylvania
Celebrating our 25th anniversary, BFTP/SEP is the region's catalyst for Stimulating Entrepreneurial Potential. Ben Franklin invests in innovative enterprises and creates commercialization pathways that generate wealth through science and technology. Part of a statewide network in Pennsylvania, BFTP/SEP provides entrepreneurs and established businesses with the Capital, Knowledge and Networks to compete in the global marketplace. BFTP/SEP has provided more than $130 million to grow more than 1,600 regional enterprises. BFTP/SEP is a founding partner of The Nanotechnology Institute(TM) (NTI), the Mid-Atlantic Nanotechnology Alliance (MANA(R)), Emerald Stage2 Venture Fund and the Minority Angel Investor Network. BFTP/SEP is part of the Commonwealth of Pennsylvania's Ben Franklin Technology Partnership. www.sep.benfranklin.org
For more information, please click here
Copyright © PR Newswire Association LLC.
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
News and information
New organic molecule shatters phosphorescence efficiency records and paves way for rare metal-free applications July 5th, 2024
Single atoms show their true color July 5th, 2024
New method cracked for high-capacity, secure quantum communication July 5th, 2024
Searching for dark matter with the coldest quantum detectors in the world July 5th, 2024
VC/Funding/Angel financing/Loans/Leases/Crowdfunding
Graphene Flagship start-up Bedimensional closes a second €10 million investment round February 10th, 2023
180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021
Nanomedicine
The mechanism of a novel circular RNA circZFR that promotes colorectal cancer progression July 5th, 2024
Diamond glitter: A play of colors with artificial DNA crystals May 17th, 2024
Advances in priming B cell immunity against HIV pave the way to future HIV vaccines, shows quartet of new studies May 17th, 2024
Announcements
New organic molecule shatters phosphorescence efficiency records and paves way for rare metal-free applications July 5th, 2024
Single atoms show their true color July 5th, 2024
New method cracked for high-capacity, secure quantum communication July 5th, 2024
Searching for dark matter with the coldest quantum detectors in the world July 5th, 2024
![]() |
||
![]() |
||
The latest news from around the world, FREE | ||
![]() |
![]() |
||
Premium Products | ||
![]() |
||
Only the news you want to read!
Learn More |
||
![]() |
||
Full-service, expert consulting
Learn More |
||
![]() |